Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories Intl (NY: CRL )

186.34 -1.40 (-0.74%)
Streaming Delayed Price Updated: 1:57 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Charles River Laboratories Intl

< Previous 1 2 3 4 5 6 7 8 9 Next >
Charles River Laboratories to Present at UBS and Jefferies Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Announces Third-Quarter 2024 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Launches New Retrogenix® Non-Human Protein Library
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Provides Translational Expertise at Neuroscience 2024
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Charles River Laboratories Announces Second-Quarter 2024 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Collaborates with Patient Advocacy Group, FOXG1 Research Foundation to Advance Rare Disease Gene Therapy Development
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River to Perform Plasmid Manufacturing for AAVantgarde
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at William Blair and Jefferies Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Announces First-Quarter 2024 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River to Perform Plasmid Production for Ship of Theseus
From Charles River Laboratories International, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.